Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury
New England Journal of Medicine, 2026 · Multicenter randomized noninferiority trial, stopped early; 535 patients in the intention-to-treat analysis
What the trial found
Major adverse kidney events occurred in 78.1% versus 71.6%; intermittent therapy did not establish noninferiority. Day-90 death occurred in 63.1% versus 53.5% (mortality hazard ratio 1.30, 95% CI 1.04–1.63).
Current guideline position
This trial must be interpreted alongside indication-specific guidance; its result alone does not establish a universal treatment policy.
Clinical interpretation
The mortality signal favors continuous initial therapy in this population. Reassess blanket modality-equivalence claims, while recognizing early stopping and context; this does not prove that CRRT is superior for every ICU patient.
Limitations
Sepsis-AKI microcirculatory decoupling, KDIGO staging, Furosemide Stress Test (FST), urine microscopy, and the AEIOU dialysis threshold framework.
Principles of convection vs diffusion, filtration fraction, delivered effluent dosing (20–25 mL/kg/h), Regional Citrate Anticoagulation, and citrate toxicity.